We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.58B
AUM Growth
+$636M
Cap. Flow
+$643M
Cap. Flow %
17.97%
Top 10 Hldgs %
40.4%
Holding
113
New
37
Increased
33
Reduced
14
Closed
23

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$210M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$166M
3
RGEN icon
Repligen
RGEN
+$118M
4
ARWR icon
Arrowhead Research
ARWR
+$87M
5
IMCR icon
Immunocore
IMCR
+$70.6M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$191M
2
TERN
Terns Pharmaceuticals
TERN
+$144M
3
DXCM icon
DexCom
DXCM
+$84.6M
4
MRK icon
Merck
MRK
+$81.6M
5
TYRA icon
Tyra Biosciences
TYRA
+$76.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
26
DELISTED
Nuvalent
NUVL
$49.4M 1.38%
481,715
+435,715
+947% +$44.4M
COGT icon
27
Cogent Biosciences
COGT
$6.65B
$47.4M 1.32%
+1,230,888
New +$45.5M
ANRO icon
28
Alto Neuroscience
ANRO
$1.05B
$46.4M 1.3%
2,064,075
-420,925
-17% -$7.8M
RAPP
29
Rapport Therapeutics
RAPP
$1.96B
$44.9M 1.26%
1,436,229
+326,229
+29% +$9.18M
IRON icon
30
Disc Medicine
IRON
$2.96B
$44.8M 1.25%
700,000
-35,000
-5% -$2.43M
UTHR icon
31
United Therapeutics
UTHR
$22B
$44.5M 1.24%
+75,000
New +$37.4M
CLDX icon
32
Celldex Therapeutics
CLDX
$2.99B
$38.8M 1.09%
1,224,165
+59,165
+5% +$1.61M
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$37.2M 1.04%
1,850,000
-40,000
-2% -$645K
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.06B
$37.2M 1.04%
639,900
+39,900
+7% +$1.84M
SLDB icon
35
Solid Biosciences
SLDB
$794M
$36M 1.01%
5,000,000
-815,000
-14% -$5.24M
DRUG
36
Bright Minds Biosciences
DRUG
$719M
$35.9M 1%
+492,319
New +$39.6M
PTGX icon
37
Protagonist Therapeutics
PTGX
$8.79B
$34.4M 0.96%
+326,159
New +$28.9M
DNLI icon
38
Denali Therapeutics
DNLI
$3.65B
$34M 0.95%
1,773,326
+1,308,326
+281% +$26M
REGN icon
39
Regeneron Pharmaceuticals
REGN
$78.5B
$30.9M 0.86%
+40,000
New +$30.6M
WAT icon
40
Waters Corp
WAT
$37B
$29.8M 0.83%
+100,000
New +$34.2M
VKTX icon
41
Viking Therapeutics
VKTX
$3.7B
$29.7M 0.83%
+914,147
New +$29.4M
INSP icon
42
Inspire Medical Systems
INSP
$1.45B
$27.8M 0.78%
+539,269
New +$37.8M
CBIO
43
Crescent Biopharma
CBIO
$537M
$27.6M 0.77%
1,500,000
– –
TRVI icon
44
Trevi Therapeutics
TRVI
$2.59B
$25.8M 0.72%
+2,166,504
New +$24.3M
LXEO icon
45
Lexeo Therapeutics
LXEO
$324M
$25.7M 0.72%
4,475,000
– –
SLNO
46
DELISTED
Soleno Therapeutics
SLNO
$24.4M 0.68%
+730,000
New +$28.6M
BBNX
47
Beta Bionics
BBNX
$577M
$22.2M 0.62%
2,211,518
+1,611,518
+269% +$23.8M
NKTR icon
48
Nektar Therapeutics
NKTR
$2.39B
$20.5M 0.57%
+285,000
New +$16.2M
CYTK icon
49
Cytokinetics
CYTK
$10.5B
$19.8M 0.55%
+300,000
New +$19.1M
AZN icon
50
AstraZeneca
AZN
$263B
$19.7M 0.55%
+100,000
New +$19.3M
1
2
3 4 5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Vestal Point Capital held 113 positions worth $3.58B, up 22% from $2.94B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Vestal Point Capital deployed $643M of net new capital in Q1 2026, opening 37 new positions and adding to 33 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,250,000 shares worth $165M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $144M trimmed.

  • Vestal Point Capital's largest Q1 2026 buy was Neurocrine Biosciences: 1,250,000 shares worth $165M.
  • Vestal Point Capital added most to Revolution Medicines in Q1 2026, an estimated $210M increase.
  • Vestal Point Capital's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $144M.
  • Vestal Point Capital fully exited Arcellx in Q1 2026, selling an estimated $191M.
  • Vestal Point Capital's ten largest holdings make up 40% of its $3.58B portfolio in Q1 2026.
  • Vestal Point Capital opened 37 new positions and closed 23 in Q1 2026.
  • Vestal Point Capital's portfolio value rose 22% quarter-over-quarter to $3.58B.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.